Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status



Status:Completed
Conditions:Breast Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/2/2016
Start Date:May 2005
End Date:May 2015
Contact:Les Roche, RN
Email:lesroche@stanford.edu
Phone:(650) 724-5913

Use our guide to learn which trials are right for you!

To Prospectively Evaluate the Potential for Simple, Effective Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status

To compare the effectiveness of usual treatments for lymphedema (massage and elastic
sleeve), instituted even before the development of swelling, compared to the use of a newly
marketed device, the Flexitouch®, which electronically simulates the effect of massage upon
lymph flow.

The current investigation is designed to prospectively evaluate the potential for simple,
effective lymphedema prophylaxis in breast cancer survivors who show early evidence of
high-risk status. There is growing evidence that the mechanisms of lymphatic repair after
injury are mediated through lymphatic flow. Accordingly, we propose that physical measures
designed to prophylactically augment lymphatic flow after surgical interventions for breast
cancer will reduce the incidence and degree of lymphatic stagnation when compared to
patients who receive conventional 'watch and wait' interventions.

The specific aims of the study are

1. to prospectively assess the presence of newly developing lymphedema in each study
subgroup through serial assessment of segmental interstitial fluid content by multiple
frequency bioimpedance

2. to evaluate the preventive interventions in a prospective, randomized fashion,
contrasting the responses of equivalent numbers of patients randomized to 2
experimental arms and the control arm of the study

3. to correlate the bioimpedance findings with concurrently derived, serial assessments of
limb volume

Recent advances in our comprehension of the biological processes of lymphatic development
and repair suggest that these mechanisms may be able to be manipulated to enhance the
regenerative responses in the lymphatic vasculature following injury. Breast
cancer-associated lymphedema is a prototype of such an acquired form of lymphatic
vasculature insufficiency. Clinically, this poses a substantial clinical problem. It is
estimated at one woman in four who survives a breast cancer intervention will develop
lymphedema, often progressively. The appearance of lymphedema has documented adverse effects
on physical and psychologically well-being. Our new insights into lymphatic repair suggest
that such mechanisms can be employed in a prophylactic fashion to forestall or eliminate the
development of lymphedema. This proposal is designed to investigate this hypothesis in a
prospective fashion, using a randomized trial design in 80 patients enrolled at the time of
breast cancer surgery. If the investigation documents a beneficial effect of preventive
measures, it could have a profound impact on subsequent breast cancer care. These measures
are simple and cost-effective and, could help to eliminate the impact of a substantial
detractor to the improved longevity and health that breast cancer survivors otherwise may
expect to enjoy.

Inclusion Criteria:

1. Patients referred to the surgeons of the Stanford University Breast Cancer Program

2. Patients will be required to have the capacity to provide informed consent.

3. All experimental protocols will be reviewed and approved by the Stanford
Institutional Review Board for the Protection of Human Subjects.

4. All of the subjects to be enrolled in the proposed studies will be patients with
unilateral breast cancer who are scheduled to undergo breast surgery and axillary
lymph node dissection, with or without breast conserving techniques.

Exclusion Criteria:

1. Patients with other serious systemic illness (renal failure, hepatic dysfunction,
congestive heart failure, neurological or psychological impairment) that would
confound the study or impair the patients' ability to participate.

2. Patients with recurrent breast cancer or other forms of pre-existing lymphedema will
be ineligible.
We found this trial at
1
site
291 Campus Dr
Stanford, California 94305
(650) 725-3900
Stanford University School of Medicine Vast in both its physical scale and its impact on...
?
mi
from
Stanford, CA
Click here to add this to my saved trials